Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson’s Disease to be Presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases
09 mars 2017 16h05 HE
|
Prothena Corporation Plc
Investor webcast planned for April 2, 2017 at 9:00 AM EDT to discuss Phase 1b study results Prothena and Roche to co-host symposium on alpha-synuclein pathology and non-motor manifestations in...
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares
03 mars 2017 08h30 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, March 03, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Announces Public Offering of Ordinary Shares
02 mars 2017 16h01 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update
14 févr. 2017 16h05 HE
|
Prothena Corporation Plc
Net cash used in operating and investing activities was $41.1 million in the fourth quarter and $133.9 million for the full year 2016; year-end cash and restricted cash position of $391 million...
Prothena to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
08 févr. 2017 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Report Fourth Quarter and Full Year 2016 Financial Results and Host Webcast Conference Call on February 14
01 févr. 2017 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Participate in the J.P. Morgan Healthcare Conference
04 janv. 2017 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Announces Appointment of Chief Regulatory Officer
15 déc. 2016 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization...
First-In-Human Assessment of PRX002, Prothena’s Anti-Alpha Synuclein Antibody for Parkinson’s Disease, Published in Movement Disorders Journal
13 déc. 2016 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease
09 nov. 2016 16h05 HE
|
Prothena Corporation Plc
All dose levels of PRX002 found to have an acceptable safety and tolerability profile, meeting the primary objective of this studyRobust central nervous system (CNS) penetration demonstrated by a...